ADAKVEO (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
ADAKVEO
Date registered
Evaluation commenced
Decision date
Approval time
215 (255 working days)
Active ingredients
crizanlizumab
Registration type
NCE/NBE
Indication
ADAKVEO (concentrate solution for infusion) is indicated for the prevention of recurrent vaso-occlusive crises in patients aged 16 years and older with sickle cell disease.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.